On the afternoon of August 11, 2015, the Deputy Minister of Health, Assoc. Prof. Dr. Pham Le Tuan, visited the headquarters and inspected the factory of Imexpharm Pharmaceutical Joint Stock Company in Cao Lanh City, Dong Thap Province. The visit also included a working session with the company's Board of Directors.

The delegation from the Ministry of Health (MOH) included: Dr. Nguyen Van Tien, Deputy Chair of the National Assembly's Committee for Social Affairs, MSc. Le Thanh Cong, Deputy Director of the Department of Finance and Planning (MOH), MSc. Nguyen Huu Tuan, Head of Investment Division, Department of Finance and Planning (MOH), MSc. Duong Duc Thien, Secretary to the Deputy Minister, Mr. Nguyen Quy Son, Chairman of the Members' Council of the Vietnam Pharmaceutical Corporation, Mr. Nguyen Duc Son, General Director of the Vietnam Pharmaceutical Corporation, and Dr. Nguyen Viet Hung, Deputy Director of the Drug Administration of Vietnam.

In addition, Dr. Vo Anh Ho, Director of the Department of Health of Dong Thap Province, represented the provincial leadership.

During the working session, People’s Doctor, Pharmacist Tran Thi Dao, General Director of Imexpharm, presented a summary report on the company's business and investment activities. She also highlighted challenges faced by pharmaceutical companies, particularly those investing in quality improvements, under the hospital tender regulations in recent years. These challenges have adversely impacted the development of the domestic pharmaceutical industry. Taking this opportunity, Imexpharm formally submitted specific and reasonable recommendations to the Deputy Minister of Health.

The delegation also heard contributions from representatives of the National Assembly’s Committee for Social Affairs, departments and agencies of the Ministry of Health, the Vietnam Pharmaceutical Corporation, and the Dong Thap Department of Health.

In his concluding remarks, Deputy Minister Assoc. Prof. Dr. Pham Le Tuan acknowledged the feedback and recommendations from Imexpharm and provided guidance on the future direction of production and business activities in the pharmaceutical sector. He advised Imexpharm to align its strategies accordingly.

The working session concluded in an atmosphere of openness and camaraderie.